Avelumab maintenance with axitinib interruption was feasible in metastatic renal cell carcinoma responders, according to ...

Over the past 5 years, targeted therapy has significantly impacted on metastatic renal cell carcinoma (mRCC ... inhibition (tyrosine kinase inhibitor [TKI]-TKI sequence) or alternate pathway ...

Proactive onco-coaching did not improve quality of life but was linked to better overall survival in patients with metastatic ...

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...

Patients treated with tyrosine kinase inhibitors received olanzapine to address adverse effects including nausea/vomiting, ...

The rationale for using the sequence VEGFR–TKI followed by mTOR inhibitors lies ... targeted therapy has significantly impacted on metastatic renal cell carcinoma (mRCC) natural history and ...

Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a ...

Proton pump inhibitors and antibiotics increase mortality risk, while statins, renin-angiotensin system inhibitors.

According to Laurence Albiges, MD, PhD, treatment of RCC with cabozantinib, nivolumab, and ipilimumab can cause potentially ...

Exelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which ...

American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 ...

The drug is also approved in the U.S. for the treatment of adults with advanced renal cell carcinoma following a PD-1/PD-L1 inhibitor and a VEGF-TKI.